Lansoprazole Capsule, Delayed Release Pellets
Product Images NDC 0378-8015

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 0378-8015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole Structural Formula (Image 01)

Chemical structure of lansoprazole, showing molecular connections including a benzene ring, sulfinyl group, and substituted pyridine ring, consistent with the active ingredient lansoprazole.*

FDA Label Image

Lansoprazole Delayed-release Capsules, Usp 15 mg Bottle Label (Image 02)

A line graph showing mean severity of day heartburn scores over a 60-day treatment period for evaluable patients. The x-axis represents days from the start of treatment, and the y-axis shows mean severity of day heartburn on a scale from 0 (none) to 3 (severe). Three lines compare placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD, with both lansoprazole doses showing lower heartburn severity than placebo.*

FDA Label Image

Lansoprazole Delayed-release Capsules, Usp 30 mg Bottle Label (Image 03)

A line graph depicting the mean severity of night heartburn over days from start of treatment in evaluable patients. The x-axis shows days from -5 to 60, and the y-axis shows mean severity ranging from 0 (None) to 3 (Severe). Three lines represent Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, showing decreasing heartburn severity over time with Lansoprazole treatments compared to placebo.*

FDA Label Image

Figure 1 (Image 04)

Label for Lansoprazole 15 mg delayed-release capsules, USP by Mylan Pharmaceuticals Inc. The label shows the NDC 0378-8015-93 and states the product contains enteric-coated pellets. Packaging contains 30 capsules with dosing and storage instructions. Manufactured in India, with a barcode and child-resistant closure instructions.*

FDA Label Image

Figure 2 (Image 05)

Label for Lansoprazole delayed-release capsules, USP 30 mg by Mylan Pharmaceuticals Inc. The label includes dosage form as capsules with delayed-release pellets, the strength of 30 mg, and a package size of 30 capsules. The label features storage instructions, manufacturer information, and an NDC barcode. It also instructs dispensing a medication guide to patients and notes the container is child-resistant.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.